Pregled bibliografske jedinice broj: 1116125
A pilot investigation of accelerated deep transcranial magnetic stimulation protocols in treatment-resistant depression
A pilot investigation of accelerated deep transcranial magnetic stimulation protocols in treatment-resistant depression // European Archives of Psychiatry and Clinical Neuroscience, 271 (2020), 1; 49-59 doi:10.1007/s00406-020-01141-y (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1116125 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
A pilot investigation of accelerated deep
transcranial magnetic stimulation protocols in
treatment-resistant depression
Autori
Filipčić, Igor ; Šimunović Filipčić, Ivona ; Sučić, Strahimir ; Milovac, Željko ; Gereš, Natko ; Matić, Katarina ; Čelić-Ružić, Mirela ; Zečević Penić, Sandra ; Orgulan, Ivana ; Požgaj, Vladimir ; Bajić, Žarko
Izvornik
European Archives of Psychiatry and Clinical Neuroscience (0940-1334) 271
(2020), 1;
49-59
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Deep repetitive transcranial magnetic stimulation ; Accelerated ; Treatment-resistant depression ; Depression
Sažetak
Accelerated repetitive transcranial magnetic stimulation (rTMS) protocols are being increasingly studied because of their potential to provide quicker and enhanced treatment efficacy. However, there is a lack of accelerated deep TMS with H1-coil (adTMS) treatment research. This randomized pilot study investigated the efficacy and safety of adTMS protocols. Twenty- eight TRD patients received 20-min sessions twice daily for 10 or 15 days. Primary outcomes were changes in Hamilton Depression Rating Scale (HDRS) scores and discontinuation because of adverse events (AE). Secondary outcomes were response, remission, daily changes in Beck Depression Inventory-II (BDI-II) scores, and AE incidence. HDRS scores decreased by 13 (95% CI 11-17 ; 59%, 95% CI 45-73%) and 13 (95% CI 11-14 ; 62%, 95% CI 54-69%) points in the 10- and 15-day protocols, respectively. The adjusted difference between the two protocols was not significant or clinically relevant. Remission was achieved by 38% and 42% after 10-day and 15-day protocols, respectively. The intervention was discontinued because of AEs in 3/33 (9%) patients. The BDI-II decreases were significant and clinically relevant during the first 8 days. Twice-daily adTMS for 10 days seems to be safe and effective, with rapid clinical benefits during the first week of treatment. These promising results warrant further investigation in larger randomized clinical trials comparing adTMS with the standard dTMS protocol.
Izvorni jezik
Engleski
Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb,
Psihijatrijska bolnica "Sveti Ivan" Zagreb,
Fakultet za dentalnu medicinu i zdravstvo, Osijek
Profili:
IVONA ŠIMUNOVIĆ FILIPČIĆ
(autor)
Natko Gereš
(autor)
Željko Milovac
(autor)
Igor Filipčić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE